Liquid Biopsies in Drug Development: Where They Add Value Today & What Still Needs Work
- Where liquid biopsies are currently delivering the most value across the drug development lifecycle, and where teams remain cautious
- What are the key practical challenges of integrating liquid biopsy endpoints into clinical development programs
- What needs to change, technically, operationally, or regulatorily, to enable broader and more confident adoption